polymorphisms and cardiovascular events were assessed. Data were analyzed at baseline and longitudinally. We used multivariable-adjusted Cox regression to estimate hazard ratios (HR) for cardiovascular outcomes. The MLXIPL-rs3812316 was associated with lower baseline triglycerides (P=5.5x10 -5 ) and lower hypertriglyceridemia (odds ratio [OR] : 0.73; 95%CI, 0.63-0.85; P=1.4x10 -6 in Gcarriers versus CC). This association was modulated by baseline adherence to MedDiet (AdMedDiet). When AdMedDiet was high, the protection was stronger (OR: 0.63, 95%CI: 0.51-0.77; P=8.6x10 -6 ) than when AdMedDiet was low (OR: 0.88, 95%CI: 0.70-1.09;P=0.219). Throughout the follow-up, both the MLXIPL-rs3812316 (P=3.8x10 -6 ) and the MedDiet intervention (P=0.030) were significantly associated with decreased triglycerides. Likewise in G-carriers MedDiet intervention was associated with greater total cardiovascular risk reduction and specifically for myocardial infarction. In the MedDiet, but not in the control group, we observed lower myocardial infarction incidence in G-carriers versus CC (HR: 0.34; 95%CI:0.12-0.93;P=0.036 and 0.90; 95%CI: 0.35-2.33;P=0.830, respectively).
Conclusion: Our novel results suggest that MedDiet enhances the triglyceride-
Given that hypertriglyceridemia is re-emerging as an important cardiovascular disease risk factor [1] [2] [3] , it is essential to gain further understanding about the genes involved and the environmental factors that modulate their expression 4, 5 . Outstanding among the genes that have recently been associated with triglyceride metabolism is the MLXIPL (Max-like protein X interacting protein-like, also known as Mondo B) that encodes the carbohydrate response element binding protein (CHREBP). In a genomewide association study (GWAs) 6 , we and others reported for the first time that the MLXIPL was a new locus associated with plasma triglycerides. We found that the minor allele of the intergenic rs17145738 polymorphism, located downstream of MLXIPL, was associated with significantly lower plasma triglyceride concentrations 6 . This observation was in line with previous work in animal models in which the ChREBP, discovered by the group of Uyeda 7 , was characterized as an important transcription factor coupling hepatic glucose utilization and lipogenesis 8 . Subsequent studies in animal models confirmed the crucial role of ChREBP in regulating the process that converts excess of dietary carbohydrate into triglycerides and suggested its implication in the development of the metabolic syndrome 9, 10 . However, given the intergenic location of the rs17145738 polymorphism between the MLXIPL/TBL2 genes 6 , the direct involvement of this gene in human triglyceride metabolism was not consolidated until Kooner et al 11 identified a functional variant (rs3812316, C771G, amino acid change Gln241His), located in an evolutionarily conserved region encoding a domain implicated in the activation of MLXIPL 10 . In view of the association of the minor G allele with low triglyceride concentrations, the authors suggested a reduced MLXIPL function for this variant, consistent with the low triglycerides described in Chrebp-deficient mice 9, 12 .
The two variants rs17145738 and rs3812316 are in high linkage disequilibrium (LD), so explaining our previous results 6 . However, the existing literature provides a more heterogeneous perspective 6, 11, [13] [14] [15] [16] [17] [18] [19] [20] [21] . Although the GWAs and meta-analyses have consistently found a significant association between the minor allele and lower triglyceride concentrations 6, 11, 13, 14 , other experimental approaches have not shown the same consistency [18] [19] [20] [21] which may be due to the fact that the expression of this gene and its biological consequences have been shown to be strongly modulated by diet (i.e., total fat, polyunsaturated fatty acids, total carbohydrates, or fructose) 7, 8, 12, 22, 23 . Thus, unexplored gene-diet interactions might be affecting the outcomes of human studies.
Similarly, the association between MLXIPL polymorphisms and cardiovascular diseases is also heterogeneous. Although two studies on Chinese subjects 24, 25 reported significant associations between MLXIPL polymorphisms and lower risk of coronary artery disease, such an association has not been supported in meta-analyses 13, 26 . Therefore, the aims of the present study were: 1) to assess the impact of the MLXIPLrs3812316 polymorphism on triglyceride concentrations as well as the modulating effects of the Mediterranean diet (MedDiet) at baseline and longitudinally; 2) to study the association between this polymorphism and major cardiovascular events (myocardial infarction and stroke incidence), as well as its modulation through longterm intervention (mean ≈5 years) with MedDiet; and 3) To analyze whether the effects of the MedDiet intervention on cardiovascular events is modulated by the MLXPIL-rs3812316 polymorphism.
METHODS
Detailed Methods are included in the Supplement.
Subjects
We studied 7,161 participants (3,049 men and 4,112 women) in the PREDIMED (PREvención with DIeta MEDiterránea) trial (27) from whom DNA was available and the MLXIPL-rs3812316 determined. The PREDIMED is a multi-center, randomized, controlled clinical trial (controlled-trials.com number, ISRCTN35739639) aimed at assessing the effects of the MedDiet on the primary prevention of cardiovascular disease 27, 28 . The completion date of this study was December 2010 and the total number of randomized subjects was 7,447. The 7,166 participants included did not differ in the main characteristics from those of the total cohort. From October 2003 physicians in Primary Care Centers selected potential high cardiovascular risk subjects (Detailed in the Supplement). Participants were randomly assigned to these interventions: MedDiet with extra-virgin olive oil (EVOO), MeDiet with mixed nuts and control group (low-fat diet). Participants assigned to both MedDiet groups received intensive training to follow the MedDiet and allotments of either extra virgin olive oil or mixed nuts (30 g/d) 27, 28 . Participants assigned to the control diet received recommendations to reduce the intake of all types of fat 27 . Participants were followed for a median of 4.8 years (interquartile range, 2.8 to 5.8 years).
Demographic, clinical, anthropometric and dietary measurements
The baseline examination included assessment of standard cardiovascular risk factors, medication use, socio-demographic factors and lifestyle variables 27, 28 . The level of adherence to the MedDiet (AdMedDiet) was measured by a validated 14-item questionnaire 29 . It consisted of 14 questions on food consumption frequency and habits characteristic of the MedDiet (Supplemental Table 1 ). Each question was scored 0 or 1.
Outcome ascertainment
The primary endpoint was the occurrence of the first major cardiovascular event and comprised myocardial infarction, stroke or cardiovascular death as detailed in the Supplement and elsewhere
27
. End-points confirmed by the committee occurring between October 1, 2003, and December 1, 2010 were included in the analyses.
Biochemical determinations, DNA extraction and genotyping
Blood samples were obtained after an overnight fast and were frozen at -80ºC.
Fasting glucose, total cholesterol, triglycerides, HDL-C and LDL-C were measured using standard enzymatic methods
28
.
Genomic DNA was extracted from buffy-coat. We genotyped the intergenic MLXIPL-rs17145738 (in a sub-sample consisting of 1016 participants recruited in the Valencia region) and the nonsynonymous (Gln241His) rs3812316 polymorphism (in the whole sample) on a 7900HT Sequence Detection System (Applied Biosystems, Foster City, CA, USA) using a fluorescent allelic discrimination TaqManTM assay with a calling rate >95%. 5% of samples were randomly selected and genotyped a second time and no discrepancies were found. Genotype frequencies did not deviate from HardyWeinberg equilibrium expectations (P=0.069 for the rs17145738 and P= 0.187 for the rs3812316). We found strong linkage disequilibrium (LD) between both polymorphisms (D': 0.955; r 2 : 0.895; P<0.001). Consistent with our previous findings 6 , the intergenic rs17145738 polymorphism was significantly associated with fasting triglycerides:
1.52+/-0.93 mmol/L in CC vs. 1.34+/-0.77 mmol/L in T carriers; P=0.004, and we decided to continue the main study with the functional MLXIPL-rs3812316 polymorphism.
Statistical Analyses
LD was assessed with the Haploview software package. Chi-square tests were used to test differences in percentages. Triglycerides were log-transformed for the statistical analyses. Hypertriglyceridemia was defined as a fasting triglyceride level >1.7 mmol/l. MLXIPL polymorphisms were first tested as additive and further, carriers of the variant allele were grouped together (dominant model) due to the low prevalence of the variant allele. To compare crude means we applied t and ANOVA tests. MedDiet during follow-up on major cardiovascular events depending on the MLXIPLrs3812316 polymorphism. In this case, HR and 95% CI for the MedDiet intervention were stratified by the polymorphism. We also analyzed the influence of baseline triglyceride concentrations on cardiovascular events in the Cox regression models.
Analyses were based on the intention-to-treat principle. In multivariable model 1 (basic model) we adjusted for sex, age, center and intervention group. Multivariable models 2 and 3 included additional adjustments as detailed. Kaplan-Meier survival curves were plotted to estimate the probability of remaining free of myocardial infarction during follow-up. Statistical analyses were performed with the IBM SPSS Statistics version 21.0, NY. All tests were two-tailed and p values <0.05 were considered statistically significant.
RESULTS
Prevalence of the MLXIPL-rs3812316 (C>G, Gln241His) genotypes were:
83.2% CC, 15.4% CG, and 0.9% GG. Table 1 shows baseline demographic, biochemical, clinical and lifestyle characteristics of the 7,166 participants by the MLXIPL-rs3812316 polymorphism. There were no significant differences in sex, age, BMI, dietary intake, smoking, drinking, physical activity, type 2 diabetes, hypertension, or treatment with lipid lowering drugs between genotypes. Likewise, we found no significant differences of genotype distribution among intervention groups (MedDiet groups or control diet). Characteristics of the study participants according to the randomly assigned dietary intervention groups at baseline are shown in Supplemental Table 2 .
Baseline association between the MLXIPL-rs3812316 polymorphism and plasma lipid concentrations and fasting glucose and type 2 diabetes
We observed ( Table 2 ) a strong association between this polymorphism and lower triglyceride concentrations [B: -0.11 mmol/l (-9.86 mg/dl) per variant G-allele, 95% CI: -0.17, -0.06; P=5.5x10 -5 ] in the entire population. This association remained statistically significant after multivariable adjustment for potential confounders (models against hypertriglyceridemia (triglycerides>1.7 mmol/l), for carriers of the minor Gallele in comparison with CC homozygotes. Moreover, we detected a significant association with fasting glucose that was higher in GG homozygous subjects, but the effect did not show a linear trend. In a recessive model, we observed a statistically significant association (P=0.014) between the polymorphism and type 2 diabetes.
Homozygous subjects for the G-allele had lower type 2 diabetes risk in comparison with CC (OR: 0.52; 95%CI: 0.30-0.89). This association remained statistically significant after further multivariate adjustment (OR: 0.55; 95%CI: 0-32-0.95; P=0.033).
Baseline modulation of the associations between the MLXIPL-rs3812316 polymorphism and risk of hypertriglyceridemia by AdMedDiet
We found a statistically significant gene-diet interaction between the MLXIPLrs3812316 polymorphism and baseline AdMedDiet on hypertriglyceridemia (Pinteraction: 0.025, which remained statistically significant after multivariate adjustment). When AdMedDiet was high (≥9 points), the protective effect of the variant allele against hypertriglyceridemia was stronger (OR: 0.63, 95% CI: 0.51-0.77; P=8.6x10 -6 ). When AdMedDiet was low, the protection was attenuated and did not reach statistical significance (OR: 0.88, 95% CI: 0.70-1.09; P=0.219). These results remained consistent in a sensitivity analysis testing this gene-diet interaction in different sub-groups: men, women, type 2 diabetic and non-diabetic subjects ( Table 3) . We also observed a similar dietary modulation when plasma triglyceride concentrations at baseline were considered as a continuous variable (Supplemental Figure 1) .
Association between the MLXIPL-rs3812316 polymorphism and plasma triglycerides in the follow-up and modulation by the MedDiet
We analyzed the effect of this polymorphism on on-trial triglyceride concentrations (evolution of triglyceride levels over time) as well as the dietary modulation of this effect using longitudinal data from 5-year follow-up for all subjects having triglycerides measured at baseline, at 1-y, at 3-y and at 5-years (n=2,418 subjects) in a model for repeated measures. In a model adjusted for dietary intervention and other covariables (Figure 1 A) (Table 4) . No statistically significant dietary modulations were found for stroke.
Effects of the MLXIPL-rs3812316 polymorphism on the association between the intervention with MedDiet and incidence of cardiovascular diseases
We examined the effect of the dietary intervention (MedDiet versus control) by genotype on cardiovascular events and found (Supplemental Table 3 After further adjustment of these results for other covariables (hypertension, family history or cardiovascular disease, waist circumference and total cholesterol) or baseline hypertriglyceridemia, the association between the polymorphism and lower risk of myocardial infarction in the MedDiet intervention group remained statistically significant (P<0.05). In these Cox-multivariable models, baseline hypertiglyceridemia was significantly associated with higher risk of cardiovascular diseases, myocardial infarction and stroke in the whole population (all P<0.01). For myocardial infarction, we also expressed the relative risks from Cox regression with a single referent group (controls with CC -and the other 3 groups referent to that) as well as the incidence rates in Supplemental Table 4 .
DISCUSSION
In this dietary intervention study, conducted in a large cohort of high cardiovascular risk subjects we found that the MLXIPL-rs3812316 polymorphism was a In addition to the differences in linkage disequilibrium between the several variants in different populations, the observed gene-diet interaction may help explain some ethnic-and population-specific associations described for the MLXIPL polymorphisms with triglycerides in different settings and dietary intakes 6, [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [30] [31] [32] . Thus, Musunuru et al 32 observed that the MLXIPL polymorphisms were strongly associated with triglycerides in European American populations (P<0.001), but they failed to find significant associations in African Americans. Also, inter-population specific differences were noted in the multiethnic United States National Health and Nutrition Examination Survey III 18 . In the present study we focused on the overall dietary pattern by analyzing the level of adherence to the MedDiet at baseline (or MedDiet intervention in the follow-up), a healthy dietary pattern characterized by a high intake of vegetables, fruits, cereals, olive oil, fish, legumes, and nuts that is low in saturated fats and simple carbohydrates and rich in MUFA and fiber 27 . As far as we know, ours is the first study to report a gene-diet interaction between MLXIPLrs3812316 polymorphism and AdMedDiet on plasma triglycerides in humans. However, although the detailed regulation of ChREBP remains unknown, several studies in animal models have reported that diet modulates ChREBP gene expression as well as the effects on triglyceride and carbohydrate metabolism 7, 8, 22, 23, 33, 34 , so supporting our results. In the first murine ChREBP-knockout model 8 it was observed that ChREBP deficiency caused intolerance of simple carbohydrates (60% glucose or sucrose) and although ChREBP -/-mice were viable and appear to have a normal life span on a standard diet, when ChREBP-knockout mice were fed with a high-fructose (70%) diet they died within a few days. In addition to this extreme gene-diet interaction the authors also observed differences in liver triglycerides, glucose and other metabolites when ChREBP-knockout mice fed with a standard diet (standard rodent chow, Harlan Teklad Mouse/Rat Diet 7002) were compared with ChREBP-knockout mice fed with a highstarch diet (60% starch, 20% casein, 15% cellulose, 2.5% vitamins, and 2.5% minerals) and the statistical differences with wild-type mice were analyzed 8 . However, no significant effect on plasma triglycerides was detected 8 . The effect the ChREBP deficiency on reduced plasma triglycerides was more clearly observed in another work using a ChREBP-null ob/ob murine model 12 , in which a normalization of plasma triglyceride levels was detected in comparison to the high triglycerides found in ob/ob mice. Erion et al 33 , using a murine model in which expression of ChREBP was decreased with a specific antisense oligonucleotide, also observed a reduction of plasma reported a significant lower risk of coronary artery disease in carriers of the minor allele; the results of large meta-analyses (including several populations and more heterogeneity) did not confirm these findings 13, 26, 31, 35 . The protective effect of the MLXIPL-rs3812316 polymorphism on myocardial infarction can be partially explained by the interaction of MedDiet on triglycerides, but other mechanisms are probably involved. Thus, the MLXIPL locus has also been associated with VLDL particle size and concentrations 30 , coagulation Factor VII levels 36 and plasma concentrations of liver enzymes 37 .
In conclusion, we reported three novel findings on the relationships of the nonsynonymous MLXIPL-rs3812316 polymorphism with cardiometabolic outcomes.
First, in addition to triglyceride concentrations, we observed a lower risk of type 2 diabetes in homozygous subjects for the variant G-allele. Second, its association with fasting triglycerides was modulated by AdMedDiet at baseline, the protective effect of the variant G-allele against hypertriglyceridemia being stronger when AdMedDiet was high. The results obtained in the intervention study reinforced these findings. Third, intervention with MedDiet increased the beneficial effect of the variant allele against cardiovascular diseases, specifically for myocardial infarction. Given that the results stem from a large randomized intervention trial, they provide a high level of evidence, which may be important for future nutrigenetic studies. P-values and regression coefficients obtained considering additive effects in models adjusted for sex, age, center, type 2 diabetes, BMI, lipid lowering drugs, hypoglycemic drugs, smoking, drinking, physical activity and total energy intake 4: P-values for regression coefficients in model 3 additionally adjusted for blood pressure, waist circumference and family history of premature cardiovascular disease (model 4). † Biochemical data were available in 6700 subjects for total cholesterol, 6628 subjects for HDL-C, 6619 subjects for triglycerides, 6594 subjects for LDL-C and 6327 subjects for glucose Prevalence of hypertriglyceridemia depending on the polymorphism (dominant model) and dietary intervention group at baseline, 1-y, 3-y and 5-years of follow-up in all subjects having data for all the four measurements (n=2,418). OR for triglyceridemia after 5-year follow-up were estimated. CC subjects in the control group were considered the reference category. Crude and multivariable adjusted models were fitter. Models were adjusted for sex, age, center, BMI, type 2 diabetes, AdMedDiet, medications, smoking, drinking and physical activity. Incidence rate*** HR and 95% CI
Funding Sources

